AstraZeneca plc (NYSE:AZN) – Stock analysts at Leerink Swann issued their FY2022 earnings estimates for AstraZeneca in a research report issued on Thursday, according to Zacks Investment Research. Leerink Swann analyst S. Fernandez forecasts that the company will post earnings of $3.15 per share for the year. Leerink Swann has a “Market Perform” rating and a $38.00 price target on the stock.
AZN has been the subject of several other reports. JPMorgan Chase & Co. raised shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a research note on Friday, December 29th. Zacks Investment Research cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. BMO Capital Markets set a $38.00 price target on shares of AstraZeneca and gave the stock a “buy” rating in a research note on Wednesday, January 10th. Credit Suisse Group raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a research note on Monday, October 16th. Finally, ValuEngine raised shares of AstraZeneca from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 3rd. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $35.20.
Shares of AstraZeneca (AZN) traded down $0.49 during mid-day trading on Friday, reaching $33.61. 8,803,388 shares of the company’s stock traded hands, compared to its average volume of 4,510,000. The company has a quick ratio of 0.72, a current ratio of 0.80 and a debt-to-equity ratio of 0.93. The firm has a market cap of $83,560.00, a P/E ratio of 28.48, a P/E/G ratio of 2.03 and a beta of 0.74. AstraZeneca has a 52-week low of $28.43 and a 52-week high of $36.70.
AstraZeneca (NYSE:AZN) last announced its earnings results on Friday, February 2nd. The company reported $1.30 EPS for the quarter, topping the consensus estimate of $0.44 by $0.86. The firm had revenue of $5.78 billion for the quarter, compared to the consensus estimate of $5.49 billion. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. The business’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period last year, the company posted $1.21 EPS.
Several large investors have recently added to or reduced their stakes in the stock. First Republic Investment Management Inc. grew its stake in shares of AstraZeneca by 14.1% in the fourth quarter. First Republic Investment Management Inc. now owns 55,825 shares of the company’s stock valued at $1,938,000 after buying an additional 6,909 shares in the last quarter. FDx Advisors Inc. boosted its position in AstraZeneca by 8.8% during the fourth quarter. FDx Advisors Inc. now owns 156,322 shares of the company’s stock worth $5,424,000 after purchasing an additional 12,620 shares during the period. Synovus Financial Corp bought a new position in AstraZeneca during the fourth quarter worth $327,000. American International Group Inc. bought a new position in AstraZeneca during the fourth quarter worth $1,976,000. Finally, Arrowstreet Capital Limited Partnership bought a new position in AstraZeneca during the fourth quarter worth $25,455,000. 14.79% of the stock is owned by institutional investors and hedge funds.
The company also recently announced a semiannual dividend, which will be paid on Monday, March 19th. Investors of record on Friday, February 16th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Thursday, February 15th. This represents a dividend yield of 5.62%. AstraZeneca’s dividend payout ratio is presently 116.10%.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.